Research and Markets: Crohn's Disease (Event Driven).
Treatment options for Crohn's disease (CD) include conventional, largely generic small molecules and more-potent biological agents, including tumor necrosis factor-alpha (TNF-a) inhibitors. Despite the clinical and commercial success of the TNF-a inhibitors, opportunity remains for agents that can safely and effectively induce and maintain remission in a significant number of patients with moderate to severe CD.
Emerging therapies with different mechanisms of actionincluding the interleukin (IL)-12/IL-23 inhibitor ustekinumab (Janssen Biotech/Janssen Cilag's Stelara), the cell adhesion molecule (CAM) inhibitor vedolizumab (Millennium Pharmaceuticals), and the chemokine receptor inhibitor GSK-1605786 (formerly Traficet-EN or CCX-282B; GlaxoSmithKline/ChemoCentryx)are in clinical development for CD.
However, interviewed thought leaders do not expect these drugs to displace the TNF-a inhibitors as the dominant drug class for moderate to severe CD. The estimated high pricing of ustekinumab, which is already marketed for psoriasis, and concerns about the risk of progressive multifocal leukoencephalopathy (PML) for vedolizumab will have implications for the CD market.
Key Topics Covered:
- Executive Summary
- What are the key parameters of the Crohn's disease market?
- What factors are driving the market for Crohn's disease therapies?
- What factors are constraining the market for Crohn's disease therapies?
- What are the drug development activities of note in Crohn's disease?
- What do the experts say?
- What key challenges and opportunities remain?
- 1 Etiology and Pathophysiology
- 2 Epidemiology and Patient Populations
- 3 Current Therapies and Medical Practice
- 4 Unmet Needs
- 5 Emerging Therapies
- 6 Market Outlook
- Appendix A BibliographyCrohn's Disease
- Appendix B Market Forecast Methodology
- Appendix C Experts InterviewedCrohn's Disease
- Appendix D Supplemental Epidemiology BibliographyCrohn's Disease
- Tables and Figures
For more information visit http://www.researchandmarkets.com/research/7gvw98/crohns_disease
Source: Decision Resources, Inc
|Printer friendly Cite/link Email Feedback|
|Date:||Sep 20, 2012|
|Previous Article:||Research and Markets: Osteoporosis (Event Driven).|
|Next Article:||Research and Markets: Male Cancer - Pipeline Review, H2 2012.|